Pharmacogenetics of cancer therapy: Getting personal

[1] Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-K-m catalysts of cyclophosphamide and ifosfamide activation [J]. PHARMACOGENETICS, 1997, 7 (03): : 211 - 221

[2] THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS [J]. TRANSPLANTATION, 1992, 53 (05) : 1051 - 1056

[3] Czwerwinski M, 1996, DRUG METAB DISPOS, V24, P1015

[4] FAMILIAL DEFICIENCY OF DIHYDROPYRIMIDINE DEHYDROGENASE - BIOCHEMICAL BASIS FOR FAMILIAL PYRIMIDINEMIA AND SEVERE 5-FLUOROURACIL-INDUCED TOXICITY [J]. JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (01) : 47 - 51

[5] THE PURINE PATH TO CHEMOTHERAPY [J]. SCIENCE, 1989, 244 (4900) : 41 - 47

[6] ALTERED MERCAPTOPURINE METABOLISM, TOXIC EFFECTS, AND DOSAGE REQUIREMENT IN A THIOPURINE METHYLTRANSFERASE-DEFICIENT CHILD WITH ACUTE LYMPHOCYTIC-LEUKEMIA [J]. JOURNAL OF PEDIATRICS, 1991, 119 (06) : 985 - 989

[7] DIAGNOSTIC-ANALYSIS, CLINICAL IMPORTANCE AND MOLECULAR-BASIS OF DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (10) : 325 - 327

[8] MOLECULAR-GENETICS OF THE N-ACETYLTRANSFERASES [J]. PHARMACOGENETICS, 1993, 3 (01): : 45 - 50

[9] Nm23-H1: Genetic alterations and expression patterns in tumor metastasis [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (01) : 6 - 10

[10] BENEFICIAL-EFFECTS OF CONVERSION FROM CYCLOSPORINE TO AZATHIOPRINE AFTER KIDNEY-TRANSPLANTATION [J]. LANCET, 1995, 345 (8950): : 610 - 614

[1] Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-K-m catalysts of cyclophosphamide and ifosfamide activation [J]. PHARMACOGENETICS, 1997, 7 (03): : 211 - 221

[2] THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS [J]. TRANSPLANTATION, 1992, 53 (05) : 1051 - 1056

[3] Czwerwinski M, 1996, DRUG METAB DISPOS, V24, P1015

[4] FAMILIAL DEFICIENCY OF DIHYDROPYRIMIDINE DEHYDROGENASE - BIOCHEMICAL BASIS FOR FAMILIAL PYRIMIDINEMIA AND SEVERE 5-FLUOROURACIL-INDUCED TOXICITY [J]. JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (01) : 47 - 51

[5] THE PURINE PATH TO CHEMOTHERAPY [J]. SCIENCE, 1989, 244 (4900) : 41 - 47

[6] ALTERED MERCAPTOPURINE METABOLISM, TOXIC EFFECTS, AND DOSAGE REQUIREMENT IN A THIOPURINE METHYLTRANSFERASE-DEFICIENT CHILD WITH ACUTE LYMPHOCYTIC-LEUKEMIA [J]. JOURNAL OF PEDIATRICS, 1991, 119 (06) : 985 - 989

[7] DIAGNOSTIC-ANALYSIS, CLINICAL IMPORTANCE AND MOLECULAR-BASIS OF DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (10) : 325 - 327

[8] MOLECULAR-GENETICS OF THE N-ACETYLTRANSFERASES [J]. PHARMACOGENETICS, 1993, 3 (01): : 45 - 50

[9] Nm23-H1: Genetic alterations and expression patterns in tumor metastasis [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (01) : 6 - 10

[10] BENEFICIAL-EFFECTS OF CONVERSION FROM CYCLOSPORINE TO AZATHIOPRINE AFTER KIDNEY-TRANSPLANTATION [J]. LANCET, 1995, 345 (8950): : 610 - 614